Luette Semmes, MD
Dermatology · Salisbury, MDNPI 1962437590
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 935 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 935 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Lilly USA, LLC$2K
- LEO Pharma Inc.$2K
- Amgen$1K
- Sun Pharmaceutical Industries Inc.$1K
- plus $8K from 29 others
What the payments were for
- Food & beverage$19,08998%
- Education$3202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 175 | $3,467 |
| Johnson & Johnson | 92 | $2,142 |
| Lilly USA, LLC | 73 | $1,841 |
| LEO Pharma Inc. | 107 | $1,581 |
| Amgen | 57 | $1,428 |
| Sun Pharmaceutical Industries Inc. | 58 | $1,241 |
| Dermavant Sciences, Inc. | 53 | $1,054 |
| Sanofi | 39 | $1,034 |
| Pfizer | 69 | $966 |
| Novartis | 48 | $869 |
| Regeneron Healthcare Solutions, Inc. | 24 | $567 |
| E.r. Squibb & Sons, L.L.C. | 22 | $525 |
| Incyte Corporation | 15 | $321 |
| UCB, Inc. | 16 | $310 |
| Organon | 8 | $302 |
| Arcutis Biotherapeutics, Inc. | 8 | $240 |
| Mallinckrodt Hospital Products Inc. | 4 | $212 |
| Genentech USA, Inc. | 12 | $212 |
| Bristol Myers Squibb | 10 | $180 |
| Galderma Laboratories, L.p. | 10 | $172 |
| Janssen Scientific Affairs, LLC | 3 | $156 |
| Boehringer Ingelheim | 6 | $131 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $107 |
| VYNE Pharmaceuticals Inc. | 2 | $70 |
| Almirall LLC | 3 | $59 |
| Kyowa Kirin, Inc. | 2 | $39 |
| Verrica Pharmaceuticals Inc. | 2 | $36 |
| Biofrontera Inc. | 2 | $35 |
| Mission Pharmacal Company | 2 | $26 |
| Revance Therapeutics, Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $19 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| Medtronic | 1 | $14 |
| Merck | 1 | $12 |
| Prugen, Inc. Pharmaceuticals | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,409 in reported general payments places this provider in the 85th percentile of 306 dermatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 34 | $293,493 |
| Dupixent PenDupilumab | 16 | $58,312 |
| VtamaTapinarof | 17 | $23,417 |
| Tacrolimus | 101 | $16,880 |
| Ivermectin | 28 | $7,946 |
| Fluorouracil | 84 | $5,889 |
| Metronidazole | 100 | $5,339 |
| Clobetasol Propionate | 98 | $5,090 |
| Betamethasone Dipropionate | 136 | $4,965 |
| Ketoconazole | 163 | $3,376 |
| Triamcinolone Acetonide | 288 | $2,695 |
| Calcipotriene | 12 | $2,362 |
| Betamethasone Valerate | 43 | $2,141 |
| Tretinoin | 11 | $1,603 |
| Fluocinonide | 22 | $1,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dermavant Sciences, Inc.Vtama | $1,054 | $23,41717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 306 dermatology providers in Maryland.
Other dermatology in Salisbury
- Elizabeth BurkeSalisbury$17K
- Benjamin LockshinSilver Spring$4M
- Shawn KwatraBaltimore$1.1M
- Chesahna Kindred WeaverMarriottsville$837K
- Oanh LauringNottingham$763K
- Ronald PrussickN Bethesda$620K
- Rebecca KazinChevy Chase$342K
- Susan WalkerBethesda$221K
- Monte MeltzerBerlin$220K
- Valerie CallenderGlenn Dale$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.